Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study
Abstract
:1. Introduction
1.1. Background
1.2. Current State of the Subject
- hospital stay during the last 12 months,
- treatment during the last 3 months in health care facilities in countries with endemic and unknown frequency of occurrence of CPE,
1.3. What Remains to Be Known about the Subject
2. Materials and Methods
2.1. Research Tasks
- Dividing patients into groups according to accepted criteria
- Establishing the minimum size of the studied group
- Identifying comorbidities in patients from the studied groups
- Checking the conformity of the distributions of analysed variables with normal distribution
- Checking the relationship between the distinguished factors and a positive result of a swab for CPE
- Establishing the impact of individual factors on the swab’s result
2.2. Study Design
- ❖
- GP care centre Poradnia Lekarzy Rodzinnych MEJAmed Sp. z o.o. Łódź, ul. Przybyszewskiego 32/34 in Łódź
- ❖
- M. Kopernik Province Multi-Specialist Oncology and Traumatology Centre in Łódź, 93-513 Łódź, ul. Pabianicka 62
- ❖
- WAM University Clinical Hospital—Central Veteran’s Hospital, 90-549 Łódź, ul. Żeromskiego 113
2.3. Selection, Sample and Procedure
- The first group were hospitalised patients, who were not tested for carbapenemase producing Enterobacteriaceae (CPE) as a result of an infection.
- The second group included patients treated under home conditions and requiring care.
- The third group included chronically dialysed patients.
- Inoculation of material (anal swab) onto chromogenic media (Agar ChromID CARBA, BioMerieux).
- Incubation at a temperature of 37 °C for 24 h.
- For all growing colonies identification with the MALDI TOF method (Vitek MS, Biomerieux).
- For Gram (-) rods of the Enterobacterales order:
- antimicrobial susceptibility testing for carbapenems (ertapenem, meropenem) using the disc diffusion test.
- conducted phenotypic testing for detection of carbapamenases in accordance with the recommendations of the National Reference Centre for Antimicrobial Susceptibility Testing of Microorganisms (KORLD, Krajowy Ośrodek Referencyjny ds. Oznaczania Lekowrażliwości Drobnoustrojów) (“Detection of carbapanemases—recommendations 2017”), available at the website www.kordl.edu.pl).
- In case a positive result was obtained (carbapamenases were detected) the strain was sent to KORLD to obtain confirmation.
2.4. Analysis
3. Results
4. Discussion
5. Conclusions
- A strong correlation of CPE asymptomatic carrier status was observed only with dementia, heart failure, connective tissue diseases, and having a leukocyte level deviating from the norm. A weak correlation of CPE asymptomatic carrier status was observed with a stay at the orthopaedics ward.
- In the studied group of patients CPE asymptomatic carriers were identified, which indicates the need for further research to better identify the risk groups for a positive result of a test for CPE.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 2022, 399, 629–655. [Google Scholar] [CrossRef] [PubMed]
- Segagni Lusignani, L.; Presterl, E.; Zatorska, B.; Van den Nest, M.; Diab-Elschahawi, M. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011–2016) case-control study. Antimicrob. Resist. Infect. Control. 2020, 9, 18. [Google Scholar] [CrossRef] [Green Version]
- A Bonomo, R.; Burd, E.M.; Conly, J.; Limbago, B.M.; Poirel, L.; A Segre, J.; Westblade, L.F. Carbapenemase-Producing Organisms: A Global Scourge. Clin. Infect. Dis. 2018, 66, 1290–1297. [Google Scholar] [CrossRef] [Green Version]
- Logan, L.K.; Weinstein, R.A. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J. Infect. Dis. 2017, 215 (Suppl. S1), S28–S36. [Google Scholar] [CrossRef] [Green Version]
- Chotiprasitsakul, D.; Srichatrapimuk, S.; Kirdlarp, S.; Pyden, A.D.; Santanirand, P. Epidemiology of carbapenem-resistant Enterobacteriaceae: A 5-year experience at a tertiary care hospital. Infect. Drug Resist. 2019, 12, 461–468. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data (accessed on 20 February 2022).
- Ojdana, D.; Sacha, P.T.; Gutowska, A.; Majewski, P.; Wieczorek, P.; Tryniszewska, E.A. Profile oporności na antybiotyki pałeczek Klebsiella pneumoniae wytwarzających karbapenemazy (Profiles of antibiotic resistance of carbapemenase producing Klebsiella pneumoniae). Available online: http://mavipuro.pl/czasopisma/zakazenia-xxi-wieku/archiwum-2/zakazenia-xxi-wieku-2019-3/ (accessed on 20 February 2022).
- Ambler, R.P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1980, 289, 321–331. [Google Scholar] [CrossRef] [PubMed]
- Davido, B.; Moussiegt, A.; Dinh, A.; Bouchand, F.; Matt, M.; Senard, O.; Deconinck, L.; Espinasse, F.; Lawrence, C.; Fortineau, N.; et al. Germs of thrones—Spontaneous decolonization of Carbapenem-Resistant Enterobacteriaceae (CRE) and Vancomycin-Resistant Enterococci (VRE) in Western Europe: Is this myth or reality? Antimicrob. Resist. Infect. Control. 2018, 7, 100. [Google Scholar] [CrossRef] [Green Version]
- Available online: http://pm.microbiology.pl/zmiany-w-taksonomii-γ-proteobacteria-modyfikacja-nazwy-rzedu-enterobacteriales-i-nowe-rodziny-w-obrebie-e (accessed on 20 February 2022).
- Kelly, A.M.; Mathema, B.; Larson, E.L. Carbapenem-resistant Enterobacteriaceae in the community: A scoping review. Int. J. Antimicrob. Agents 2017, 50, 127–134. [Google Scholar] [CrossRef]
- Guidance on the Definition of Healthcare Associated Gram-Negative Bloodstream Infections. Available online: https://www.england.nhs.uk/wp-content/uploads/2020/08/HCA_BSI_definitions_guidance.pdf (accessed on 20 February 2022).
- Magiorakos, A.P.; Burns, K.; Baño, J.R.; Borg, M.; Daikos, G.; Dumpis, U.; Lucet, J.C.; Moro, M.L.; Tacconelli, E.; Simonsen, G.S.; et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: Guidance from the European Centre for Disease Prevention and Control. Antimicrob. Resist. Infect. Control. 2017, 6, 113. [Google Scholar] [CrossRef]
- Wang, G.; Zhao, G.; Chao, X.; Xie, L.; Wang, H. The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae. Int. J. Environ. Res. Public Health 2020, 17, 6278. [Google Scholar] [CrossRef]
- Halik, J. Metodyka Pisania Pracy Magisterskiej i Studyjnej (Methodology of Writing a Master’s Thesis and Conceptual Design); AON: Warszawa, Poland, 2002; p. 70. [Google Scholar]
- State as of 31.12.2019. Of Course One May Consider whether the Entire Population in Poland Is at Risk of a Infection, however Assuming A Larger Number of Persons in the Population does not Impact the Limitations in the Inference. Available online: www.stat.gov.pl (accessed on 20 February 2022).
- Available online: http://www.statystyka1.medstat.waw.pl/wyniki/TabelaEurostat2020szac.htm (accessed on 20 February 2022).
- Rószkiewicz, M. Analiza Klienta (Client Analysis); SPSS Polska: Kraków, Poland, 2011; pp. 55, 202–204. [Google Scholar]
- Szreder, M. Istotność statystyczna w czasach big data (Statistical quality in the times of Big Data), Wiadomości Statystyczne. Pol. Stat. 2019, 64, 42–57. [Google Scholar]
- Danel, D. Poziom Istotności i Granica Rozsądku (Statistical Significance within Reason), StatSoft Polska. 2016. Available online: https://media.statsoft.pl/pdf/czytelnia/poziom_istotnosci_i_granica_rozsadku.pdf (accessed on 20 February 2022).
- Park, J.W.; Kwak, S.-H.; Jung, J.; Lee, J.-Y.; Lim, Y.-J.; Choi, H.-S.; Hong, M.-J.; Choi, S.-H.; Kim, M.-N.; Kim, S.-H. The Rate of Acquisition of Carbapenemase-Producing Enterobacteriaceae among Close Contact Patients Depending on Carbapenemase Enzymes. Infect. Chemother. 2020, 52, 39–47. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Available online: https://www.health.nsw.gov.au/Infectious/controlguideline/Pages/cpe.aspx (accessed on 20 February 2022).
- Qin, X.; Wu, S.; Hao, M.; Zhu, J.; Ding, B.; Yang, Y.; Xu, X.; Wang, M.; Yang, F.; Hu, F. The Colonization of Carbapenem-Resistant Klebsiella pneumoniae: Epidemiology, Resistance Mechanisms, and Risk Factors in Patients Admitted to Intensive Care Units in China. J. Infect. Dis. 2020, 221 (Suppl. S2), S206–S214. [Google Scholar] [CrossRef] [PubMed]
- Yi, J.; Kim, K.H. Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units. Acute Crit. Care 2021, 36, 175–184. [Google Scholar] [CrossRef] [PubMed]
- Lin, Q.; Wang, Y.; Luo, Y.; Tang, G.; Li, S.; Zhang, Y.; Mao, L.; Liu, W.; Wang, F.; Sun, Z. The Effect of Host Immunity on Predicting the Mortality of Carbapenem-Resistant Organism Infection. Front. Cell. Infect. Microbiol. 2020, 10, 480. [Google Scholar] [CrossRef]
- Rao, K.; Patel, A.; Sun, Y.; Vornhagen, J.; Motyka, J.; Collingwood, A.; Teodorescu, A.; Baang, J.H.; Zhao, L.; Kaye, K.S.; et al. Risk Factors for Klebsiella Infections among Hospitalized Patients with Preexisting Colonization. mSphere 2021, 6, e0013221. [Google Scholar] [CrossRef]
- Stewardson, A.J.; Marimuthu, K.; Sengupta, S.; Allignol, A.; El-Bouseary, M.; Carvalho, M.J.; Hassan, B.; A Delgado-Ramirez, M.; Arora, A.; Bagga, R.; et al. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): A multinational prospective cohort study. Lancet Infect. Dis. 2019, 19, 601–610. [Google Scholar] [CrossRef]
- Spera, A.M.; Esposito, S.; Pagliano, P. Emerging antibiotic resistance: Carbapenemase-producing enterobacteria. Bad new bugs, still no new drugs. Infez. Med. 2019, 27, 357–364. [Google Scholar]
- Meatherall, B.L.; Gregson, D.; Ross, T.; Pitout, J.D.; Laupland, K.B. Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am. J. Med. 2009, 122, 866–873. [Google Scholar] [CrossRef]
- Mariappan, S.; Sekar, U.; Kamalanathan, A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int. J. Appl. Basic Med. Res. 2017, 7, 32–39. [Google Scholar] [CrossRef] [Green Version]
- Moghnieh, R.; Abdallah, D.; Jadayel, M.; Zorkot, W.; El Masri, H.; Dib, M.J.; Omar, T.; Sinno, L.; Lakkis, R.; Jisr, T. Epidemiology, risk factors, and prediction score of carbapenem resistance among inpatients colonized or infected with 3rd generation cephalosporin resistant Enterobacterales. Sci. Rep. 2021, 11, 14757. [Google Scholar] [CrossRef] [PubMed]
- Aung, A.-H.; Kanagasabai, K.; Koh, J.; Hon, P.-Y.; Ang, B.; Lye, D.; Chen, S.L.; Chow, A. Epidemiology and Transmission of Carbapenemase-Producing Enterobacteriaceae in a Health Care Network of an Acute-Care Hospital and Its Affiliated Intermediate- and Long-Term-Care Facilities in Singapore. Antimicrob. Agents Chemother. 2021, 65, e0258420. [Google Scholar] [CrossRef] [PubMed]
- Roux, J.; Nekkab, N.; Colomb-Cotinat, M.; Astagneau, P.; Crepey, P. Time-series modelling for the quantification of seasonality and forecasting antibiotic- resistant episodes: Application to carbapenemase-producing Enterobacteriaceae episodes in France over 2010–20. J. Antimicrob. Chemother. 2021, 76, 226–232. [Google Scholar] [CrossRef] [PubMed]
- Yan, L.; Sun, J.; Xu, X.; Huang, S. Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital. Antimicrob. Resist. Infect. Control 2020, 9, 155. [Google Scholar] [CrossRef]
The Patient’S Place of Stay | Number | % |
---|---|---|
Hospital—ICU | 67 | 28.39% |
Hospital—Haematology | 30 | 12.71% |
Hospital—Orthopaedics | 34 | 14.41% |
Hospital—Nephrology | 61 | 25.85% |
Hospital—Another ward | 1 | 0.42% |
Dialysed in hospital as outpatient procedure | 29 | 12.29% |
Outpatient clinic | 14 | 5.93% |
Total | 236 | 100.00% |
Age Category [Years] | Women [n] | Men [n] | Number of Patients [n] | % of the Study | % of Hospitalised Generally in Poland a |
---|---|---|---|---|---|
65+ | 66 | 53 | 119 b | 50.85 | 45.87 |
55–64 | 19 | 28 | 47 | 20.09 | 17.68 |
45–54 | 9 | 15 | 24 | 10.26 | 11.31 |
35–44 | 7 | 10 | 17 | 7.26 | 11.26 |
20–34 b | 14 | 13 | 27 | 11.54 | 13.88 |
Total | 115 | 119 | 234 b | 100 bc | 100 c |
Comorbidities | Number of Study Subjects [N] | Percentage of the Study Subjects [%] |
---|---|---|
Thyroid disease | 39 | 17.6 |
Arterial hypertension (HA) | 121 | 54.8 |
Type 1 diabetes | 4 | 1.8 |
Type 2 diabetes | 52 | 23.5 |
Insulin therapy | 23 | 10.4 |
TIA in medical history | - | - |
Dementia | 9 | 4.1 |
AIDS | - | - |
COPD | 12 | 5.4 |
cerebral stroke | 15 | 6.8 |
Heart failure | 46 | 20.8 |
Peripheral vascular diseases | 15 | 6.8 |
Connective tissue diseases | 7 | 3.2 |
Peptic ulcer disease | 15 | 6.8 |
Liver diseases | 12 | 5.4 |
Hemiplegia | 6 | 2.7 |
Chronic kidney failure | 81 | 36.7 |
After a kidney transplant | 2 | 0.9 |
Tumour | 39 | 17.6 |
Metastases | 7 | 3.2 |
Leukaemia | 29 | 13.1 |
Lymphoma | 3 | 1.4 |
Null Hypothesis | Significance a,b | Decision |
---|---|---|
The distribution ICU = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.312 | Assume H0 |
The distribution nephrology = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.450 | Assume H0 |
The distribution orthopaedics = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.060 | Assume H0 |
The distribution haematology = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.982 | Assume H0 |
The distribution outpatient clinic = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.471 | Assume H0 |
The distribution of age (years) is the same for category positive swab = 1 no = 0. | 0.257 | Assume H0 |
The distribution of sex (f = 1 m = 0) is the same for category positive swab = 1 no = 0. | 0.498 | Assume H0 |
The distribution of number of days in the hospital is the same for category positive swab = 1 no = 0. | 0.897 | Assume H0 |
The distribution dialysed = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.642 | Assume H0 |
The distribution surgery in the last year = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.644 | Assume H0 |
The distribution thyroid disease = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.132 | Assume H0 |
The distribution HA = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.773 | Assume H0 |
The distribution of type 1 diabetes is the same for category positive swab = 1 no = 0. | 0.697 | Assume H0 |
The distribution of type 2 diabetes is the same for category positive swab = 1 no = 0. | 0.915 | Assume H0 |
The distribution insulin = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.328 | Assume H0 |
The distribution dementia = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.002 | Reject H0 |
The distribution COPD = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.492 | Assume H0 |
The distribution stroke = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.511 | Assume H0 |
The distribution heart failure = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.039 | Reject H0 |
The distribution peripheral vascular disease = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.511 | Assume H0 |
The distribution connective tissue diseases = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.000 | Reject H0 |
The distribution peptic ulcer disease = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.511 | Assume H0 |
The distribution liver disease = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.367 | Assume H0 |
The distribution hemiplegia = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.632 | Assume H0 |
The distribution chronic kidney failure = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.493 | Assume H0 |
The distribution after a kidney transplant = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.784 | Assume H0 |
The distribution tumour = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.185 | Assume H0 |
The distribution metastases = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.604 | Assume H0 |
The distribution leukaemia = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.309 | Assume H0 |
The distribution lymphoma = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.735 | Assume H0 |
The distribution of creatinine the same for category positive swab = 1 no = 0. | 0.380 | Assume H0 |
The distribution of urea the same for category positive swab = 1 no = 0. | 0.950 | Assume H0 |
The distribution of HGB the same for category positive swab = 1 no = 0. | 0.822 | Assume H0 |
The distribution of CRP the same for category positive swab = 1 no = 0. | 0.964 | Assume H0 |
The distribution of sNIBP the same for category positive swab = 1 no = 0. | 0.470 | Assume H0 |
The distribution of dNIBP the same for category positive swab = 1 no = 0. | 0.672 | Assume H0 |
The distribution of HA the same for category positive swab = 1 no = 0. | 0.649 | Assume H0 |
The distribution pacemaker = 1 no = 0 is the same for category positive swab = 1 no = 0. | 0.737 | Assume H0 |
The distribution of normal leukocytes is the same for category positive swab = 1 no = 0. | 0.005 | Reject H0 |
Tested Value a | |||||
---|---|---|---|---|---|
Orthopaedics = 1 no = 0 | Dementia = 1 no = 0 | Connective Tissue Diseases = 1 no = 0 | Heart Failure = 1 no = 0 | Leukocytes Normal | |
Mann–Whitney U test | 691.500 | 670.000 | 662.000 | 594.000 | 420.000 |
Z | −1.880 | −13.053 | −13.593 | −12.066 | 2.810 |
Asymptotic significance (2-sided) | 0.060 | 0.002 | 0.000 | 0.039 | 0.005 |
Positive Swab = 1 no = 0 | ||
---|---|---|
Correlation Coefficient | Significance (2-Sided) | |
ICU = 1 no = 0 | −0.066 | 0.312 |
Nephrology = 1 no = 0 | 0.049 | 0.450 |
Orthopaedics = 1 no = 0 | 0.123 | 0.060 |
Haematology = 1 no = 0 | −0.001 | 0.982 |
Outpatient clinic = 1 no = 0 | −0.047 | 0.471 |
Age (years) | −0.061 | 0.257 |
Sex (f = 1 m = 0) | −0.044 | 0.498 |
number of days at the hospital | 0.008 | 0.897 |
dialysed = 1 no = 0 | −0.031 | 0.642 |
surgery within the last year = 1 no = 0 | 0.031 | 0.644 |
thyroid disease = 1 no = 0 | 0.101 | 0.132 |
arterial hypertension = 1 no = 0 | −0.020 | 0.773 |
type 1 diabetes | −0.026 | 0.697 |
type 2 diabetes | 0.007 | 0.915 |
diabetes treated with insulin = 1 no = 0 | −0.066 | 0.328 |
dementia = 1 no = 0 | 0.205 | 0.002 |
COPD = 1 no = 0 | −0.046 | 0.492 |
stroke = 1 no = 0 | 0.044 | 0.511 |
heart failure = 1 no = 0 | 0.139 | 0.039 |
peripheral vascular disease = 1 no = 0 | 0.044 | 0.511 |
connective tissue diseases = 1 no = 0 | 0.242 | 0.000 |
peptic ulcer disease = 1 no = 0 | 0.044 | 0.511 |
liver disease = 1 no = 0 | 0.061 | 0.367 |
hemiplegia = 1 no = 0 | −0.032 | 0.632 |
chronic kidney failure = 1 no = 0 | −0.046 | 0.493 |
after a kidney transplant = 1 no = 0 | −0.018 | 0.784 |
tumour = 1 no = 0 | −0.089 | 0.185 |
metastases = 1 no = 0 | −0.035 | 0.604 |
leukaemia = 1 no = 0 | 0.068 | 0.309 |
lymphoma = 1 no = 0 | −0.023 | 0.735 |
creatinine | −0.053 | 0.380 |
urea | −0.003 | 0.950 |
HGB | −0.013 | 0.822 |
CRP | −0.003 | 0.964 |
sNIBP | 0.043 | 0.470 |
dNIBP | 0.026 | 0.672 |
HA | 0.027 | 0.649 |
implanted pacemaker = 1 no = 0 | −0.023 | 0.737 |
Leukocytes normal | −0.189 | 0.005 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Timler, M.; Timler, W.; Bednarz, A.; Zakonnik, Ł.; Kozłowski, R.; Timler, D.; Marczak, M. Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. Int. J. Environ. Res. Public Health 2023, 20, 1960. https://doi.org/10.3390/ijerph20031960
Timler M, Timler W, Bednarz A, Zakonnik Ł, Kozłowski R, Timler D, Marczak M. Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. International Journal of Environmental Research and Public Health. 2023; 20(3):1960. https://doi.org/10.3390/ijerph20031960
Chicago/Turabian StyleTimler, Małgorzata, Wojciech Timler, Ariadna Bednarz, Łukasz Zakonnik, Remigiusz Kozłowski, Dariusz Timler, and Michał Marczak. 2023. "Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study" International Journal of Environmental Research and Public Health 20, no. 3: 1960. https://doi.org/10.3390/ijerph20031960
APA StyleTimler, M., Timler, W., Bednarz, A., Zakonnik, Ł., Kozłowski, R., Timler, D., & Marczak, M. (2023). Identification and Preliminary Hierarchisation of Selected Risk Factors for Carbapenemase-Producing Enterobacteriaceae (CPE) Colonisation: A Prospective Study. International Journal of Environmental Research and Public Health, 20(3), 1960. https://doi.org/10.3390/ijerph20031960